Top 10 Transient Ischemic Attack Companies

Why Is the Transient Ischemic Attack Market Expanding?

Per Market Research Future's own published Transient Ischemic Attack Market report, the global TIA market was valued at approximately USD 0.12 billion in 2024 and is projected to reach approximately USD 0.29 billion by 2032, registering a CAGR of approximately 9.24% over 2024-2032. (Note: the prior version of this Company Page cited USD 146.9 million in 2025 rising to USD 252.62 million by 2035 at a 5.64% CAGR; these figures do not match MRFR's published TIA market report and could not be independently verified, so they have been replaced with MRFR's own reported figures above.) Growth is driven by several converging forces consistent with MRFR's published market analysis.

The rising global prevalence of cerebrovascular risk factors, including hypertension, atrial fibrillation, and type 2 diabetes, in aging populations; growing clinical and public awareness of TIA as a warning sign for major stroke requiring urgent secondary-prevention intervention; continued advances in neuroimaging (CT and MRI) for diagnosis; and expanding guideline-driven pharmacotherapy across antiplatelet and anticoagulant drug classes. North America is identified by MRFR as the leading region, supported by well-developed healthcare infrastructure and high per-capita healthcare spending, while Asia-Pacific is highlighted as a high-growth region given large patient populations and rising healthcare investment.

Drugs are the major form of therapy. Antiplatelet medications (aspirin, clopidogrel, ticagrelor) and anticoagulants represent a large part of expenditures for TIAs. Neuroimaging — especially MRI with diffusion-weighted imaging (DWI) and CT angiography — remains the preferred modality for TIA workup to detect acute ischemia and identify candidates for urgent secondary prevention, as singled out in clinical guidelines.

This has been a standing recommendation in AHA/ASA guidance for over a decade, reaffirmed in more recent updates, not a single new mandate dated to 2025. Hospitals remain the main location for TIA management, and emergency and inpatient neurology resources are still concentrated in hospitals. Older adults are the dominant patient demographic, with stroke risk rising sharply with age. A smaller surgical sub-segment is carotid endarterectomy and stenting for symptomatic carotid stenosis detected after TIA workup.

Two verified 2025 clinical developments are particularly relevant to demand for TIA care pathways. First, results presented at the 17th World Stroke Congress in Barcelona on October 24, 2025 by Dr. Iain McGurgan (Wolfson Centre for Prevention of Stroke and Dementia, University of Oxford) — drawing on the long-running Oxford Vascular Study (OXVASC) population — showed that an early, intensive blood-pressure-lowering policy (target <130/80 mmHg, using remote home monitoring) after TIA or minor stroke was associated with roughly a 40% reduction in recurrent ischemic stroke and a 50% reduction in intracerebral hemorrhage over five years of follow-up, reinforcing that blood-pressure management should begin alongside antiplatelet therapy rather than afterward.

Second, the PERSIST meta-analysis led by Dr. Faizan Khan and colleagues at the University of Calgary's Cumming School of Medicine, published online in JAMA on March 26, 2025 (print May 6, 2025), pooled data from 171,068 patients across 38 studies and found a cumulative 10-year stroke incidence of 19.8% after TIA or minor stroke — approximately 1 in 5 patients — with about half of those subsequent strokes occurring more than one year after the index event. MRFR views these findings as reinforcing the case for sustained, long-term secondary-prevention pharmacotherapy and monitoring rather than the traditional 90-day follow-up window.

What Distinguishes the Leading Companies in This Market?

Across the broader cerebrovascular secondary-prevention landscape — spanning anticoagulant and antiplatelet pharmacotherapy, neuroimaging platforms, and AI-based stroke triage software — a handful of structural factors separate category leaders: depth in DOAC (direct oral anticoagulant) and antiplatelet franchises, neuroimaging platform breadth and AI integration, scale of validated AI stroke-triage deployments, and breadth of regulatory approvals supporting secondary-prevention indications.

Pharmaceutical scale defines the largest positions. Apixaban (Eliquis), co-commercialized by Bristol Myers Squibb and Pfizer, is the world's leading oral anticoagulant for stroke prevention in non-valvular atrial fibrillation, the most common embolic cause of cardioembolic TIA; BMS reported USD 14.4 billion in worldwide Eliquis revenue for FY2025. In diagnostic imaging, Siemens Healthineers' AI-Rad Companion Neuro MR and Syngo.via platforms support automated detection of acute ischemia on DWI-MRI and are deployed across the company's imaging business, which operates in more than 180 countries with direct representation in over 70.

Leading Companies Relevant to the Transient Ischemic Attack Care Pathway — MRFR Reference Table (2026)

The following companies are not ranked by MRFR specifically for a "Transient Ischemic Attack Market," as MRFR does not publish a company-ranking table for this exact market definition. Instead, this table profiles companies whose pharmaceutical, diagnostic-imaging, or AI-triage products are most directly relevant to TIA diagnosis and secondary-prevention pharmacotherapy, with figures sourced from each company's own most recent public financial disclosures (fiscal year 2025 results where available) rather than estimated TIA-specific revenue, which none of these companies discloses separately.

Detailed Company Profiles

1. Bristol Myers Squibb / Pfizer (Eliquis Alliance) | NYSE: BMY / NYSE: PFE | Princeton, NJ, USA / New York, NY, USA

The Bristol Myers Squibb-Pfizer Alliance co-commercializes apixaban (Eliquis), the world's leading oral anticoagulant for stroke prevention in non-valvular atrial fibrillation — the most common embolic cause of cardioembolic TIA. Eliquis is a direct factor Xa inhibitor approved for stroke and systemic embolism risk reduction in AF patients, as well as VTE treatment and prevention, with a safety profile showing lower intracranial bleeding risk versus warfarin in the ARISTOTLE and AVERROES trials. BMS reported USD 14.4 billion in worldwide Eliquis revenue for FY2025.

2. Siemens Healthineers AG | XETRA: SHL | Erlangen, Germany

Siemens Healthineers is a global leader in diagnostic imaging for neurological disease, with MRI, CT, and AI-powered image-analysis platforms used in TIA diagnosis and acute stroke management across more than 180 countries (direct representation in 70+). Its Magnetom MRI portfolio delivers the diffusion-weighted imaging (DWI) sequences used for acute ischemia detection, while SOMATOM CT systems support CT angiography and CT perfusion workups.

3. GE HealthCare Technologies | NASDAQ: GEHC | Chicago, Illinois, USA

GE HealthCare’s Signa MRI and Revolution CT product families provide MRI, CT, ultrasound, and AI-powered imaging solutions for TIA and acute stroke workup, as well as Pharmaceutical Diagnostics (PDx) radiopharmaceutical solutions. Total revenue for the 2025 full year was USD 20.6 billion (up 4.8%), USD 5.7 billion for the 2025 fourth quarter (up 7.1%), and USD 5.1 billion for the 2025 third quarter (up 6%). On March 31, 2025, GE HealthCare acquired the remaining 50% interest in Nihon Medi-Physics from Sumitomo Chemical for a net cash consideration of USD 271 million. The acquisition will boost capacity for radiopharmaceutical diagnostics for neurological imaging in Japan and the wider Asia-Pacific region.

4. Bayer AG | XETRA: BAYN | Leverkusen, Germany

Bayer AG's Pharmaceuticals division co-commercializes rivaroxaban (Xarelto) with a Johnson & Johnson subsidiary as a leading oral anticoagulant indicated for stroke prevention in non-valvular atrial fibrillation and treatment/prevention of VTE — indications directly relevant to embolic and atherothrombotic TIA etiologies. Xarelto sales fell sharply in 2025 as patent protection lapsed in major markets: Bayer reported Xarelto sales of approximately EUR 2.34 billion for full-year 2025, down roughly 33% versus 2024, as generic competition intensified, particularly in Europe and Japan. Bayer's total Pharmaceuticals division net sales for 2025 were approximately EUR 17.8 billion, with growth in newer products Nubeqa and Kerendia substantially offsetting the Xarelto decline at the divisional level.

5. Boehringer Ingelheim International GmbH | Private | Ingelheim, Germany

Boehringer Ingelheim is a privately held, research-intensive pharmaceutical company whose Pradaxa (dabigatran etexilate) was the first approved direct oral anticoagulant, helping establish the shift from warfarin to DOAC therapy in AF stroke prevention. Pradaxa is indicated for stroke prevention in non-valvular AF and for VTE treatment/prevention across more than 130 countries. As a private company, Boehringer Ingelheim discloses limited product-level financial detail; the most recently available company disclosure indicates Pradaxa sales fell approximately 24% in 2024 versus the prior year amid continued generic erosion, and a precise FY2025 figure has not been separately published. Jardiance, not Pradaxa, is the company's top-selling product overall.

6. Sanofi | NASDAQ: SNY / Euronext: SAN | Paris, France

Sanofi's historical Plavix (clopidogrel) franchise, originally developed with Bristol Myers Squibb, established clopidogrel as a global standard antiplatelet agent for secondary TIA and stroke prevention. While clopidogrel has transitioned almost entirely to generics in the US and Europe, Sanofi continues to report branded Plavix revenue concentrated in China and other Rest-of-World volume-based procurement markets: Sanofi's Q3 2025 filing reported Plavix net sales of EUR 223 million, up 1.3% year-over-year, with the large majority of that figure (EUR 200 million) coming from Rest-of-World markets. Sanofi's group-wide net sales for full-year 2025 were EUR 43.6 billion, up 9.9% at constant exchange rates.

7. Novartis AG | NYSE: NVS / SIX: NOVN | Basel, Switzerland

Novartis participates in the broader TIA-adjacent space primarily through antihypertensive and cardiometabolic medicines that address upstream risk factors for TIA, such as hypertension, rather than through a TIA-specific product. Following the 2023 spin-off of Sandoz, Novartis has concentrated on innovative, patent-protected therapeutics.

8. AstraZeneca PLC | NASDAQ: AZN / LSE: AZN | Cambridge, United Kingdom

AstraZeneca's Brilinta (ticagrelor) holds an FDA-approved indication, granted in November 2020, for reducing stroke risk in patients with acute ischemic stroke (NIHSS ≤5) or high-risk TIA, based on the THALES trial (n=11,016), which showed that ticagrelor plus aspirin reduced the 30-day composite risk of stroke or death by 17% versus aspirin alone (HR 0.83), at the cost of a higher rate of severe bleeding. AstraZeneca reported total FY2025 revenue of USD 58.7 billion, up 9% year-over-year.

9. RapidAI | Private | San Mateo, California, USA

RapidAI is a leading provider of AI-powered stroke and cerebrovascular triage software, with its Rapid LVO, Rapid CTP, and related modules used to automate large-vessel-occlusion detection, CT perfusion analysis, and acute ischemia identification in emergency neuroimaging workflows relevant to TIA and stroke. As of its most recent public disclosures (November 2025), RapidAI's platform is used by more than 2,500 hospitals in over 100 countries, backed by more than 700 clinical studies.

10. Viz.ai | Private | San Francisco, California, USA

Viz.ai is an AI-powered care-coordination platform for neurovascular disease, with Viz LVO, Viz CTP, and related modules used to automate large-vessel-occlusion detection and care-team notification in acute stroke and TIA triage workflows. Per the company's own January 2026 release, Viz.ai's platform is deployed in "nearly 2,000 hospitals across the United States"; the company has not recently disclosed an updated international hospital count, and earlier company materials describing 1,400+ hospitals "in the U.S. and Europe" predate this more recent US-focused figure.

M&A and Corporate Activity Tracker (2022-2026)

The following verified transactions are directly relevant to companies in the TIA-adjacent pharmaceutical and diagnostic-imaging space. Deal values are shown only where a company has publicly disclosed them; figures marked "Undisclosed" in the prior version of this tracker have been corrected where a public figure exists.

Note: the prior version of this tracker listed a 2024 Viz.ai "Series D follow-on" and a 2022 Boehringer Ingelheim minority interest in Vifor Pharma's cardiorenal pipeline; neither could be verified from public sources at the cited terms (Viz.ai's disclosed USD 100 million Series D closed in April 2022, not as a 2024 follow-on), and an AstraZeneca "global Brilinta TIA market access expansion" line item described a general regulatory process rather than a discrete, dated transaction. These items have been removed rather than restated without verification.

Verified Clinical and Innovation Signals (2025-2026)

The items below are limited to developments that could be confirmed against official company sources, peer-reviewed publications, or conference presentations.

• Bristol Myers Squibb / Pfizer (2025): Launched the Eliquis 360 Support direct-to-patient discount program (September 8, 2025), offering eligible US patients apixaban at more than 40% below list price; extended distribution to Cost Plus Drugs in April 2026. These are commercial-access initiatives rather than R&D programs, and are described as such here.

• Siemens Healthineers (FY2025): Continued deployment of the AI-Rad Companion Neuro MR platform, supporting automated white-matter lesion quantification and DWI-based ischemia detection, across its imaging installed base in 180+ countries; Imaging segment posted 6.5% comparable revenue growth in fiscal Q4 2025.

• GE HealthCare (2025): Completed the Nihon Medi-Physics acquisition (March 31, 2025, USD 271 million) to expand radiopharmaceutical diagnostics capacity relevant to neurological and cardiovascular imaging in Asia-Pacific; announced the planned USD 2.3 billion acquisition of Intelerad in Q4 2025.

• RapidAI (2025): Received five new FDA 510(k) clearances in November 2025 (Rapid DeltaFuse, Rapid LMVO, Rapid MLS, Rapid OH, Rapid Aortic), expanding the Rapid Enterprise Platform's neurology and vascular imaging capabilities across its installed base of 2,500+ hospitals in 100+ countries.